Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves

被引:44
作者
Kim, Sun-Young
Salomon, Joshua A.
Goldie, Sue J. [1 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Populat & Int Hlth Dept, Boston, MA 02115 USA
关键词
D O I
10.2471/BLT.06.038893
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective We sought to describe a method that explicitly considers both a health-care programme's cost-effectiveness and its affordability. For illustration, we apply the method to the programme to vaccinate infants against hepatitis B in the Gambia. Methods We synthesized selected data and developed a computer-based model from the societal and payer perspectives to evaluate the cost-effectiveness of routine infant vaccination against hepatitis B in the Gambia compared with no vaccination. The primary outcome measure was cost per averted disability-adjusted life year (DALY), which was expressed in 2002 US dollars. We used Monte Carlo methods for uncertainty analysis to examine the affordability of the programme from the payer's perspective, and we derived an affordability curve and cost-effectiveness affordability curves for the programme. Findings In the Gambia, vaccinating infants against hepatitis B is highly cost-effective. Compared with offering no intervention, the vaccination programme would cost US$ 28 per DALY averted from the societal perspective or US$ 47 per DALY averted from the payer's perspective. The programme also has the potential to be affordable, starting at a relatively low budget of US$ 160 000 per year. Combining the two dimensions of the outcome measure, the probability that vaccinating infants would be both cost-effective and affordable is 40% at an annual programme budget of US$ 182 000 (the estimated total programme cost from the payer's perspective), given a threshold cost-effectiveness value of US$ 47 per DALY averted. Conclusion In the face of uncertainties about both the health and economic consequences of a vaccine programme, as well as the availability and magnitude of resources needed to fund the programme, cost-effectiveness affordability curves can provide information to decision-makers about the probability that a programme will be both cost-effective and affordable: these are distinct but equally relevant considerations in resource-poor settings.
引用
收藏
页码:833 / 842
页数:10
相关论文
共 44 条
[1]  
[Anonymous], 2006, Wkly Epidemiol Rec, V81, P350
[2]  
[Anonymous], 2002, GLOBAL BURDEN DIS 20
[3]   Economic evaluation of vaccination programmes -: A consensus statement focusing on viral hepatitis [J].
Beutels, P ;
Edmunds, WJ ;
Antoñanzas, F ;
De Wit, GA ;
Evans, D ;
Feilden, R ;
Fendrick, AM ;
Ginsberg, GM ;
Glick, HA ;
Mast, E ;
Péchevis, M ;
Van Doorslaer, EKA ;
van Hout, BA .
PHARMACOECONOMICS, 2002, 20 (01) :1-7
[4]   Economic evaluations of hepatitis B immunization: A global review of recent studies (1994-2000) [J].
Beutels, P .
HEALTH ECONOMICS, 2001, 10 (08) :751-774
[5]   Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period [J].
Bortolotti, F ;
Jara, P ;
Crivellaro, C ;
Hierro, L ;
Cadrobbi, P ;
Frauca, E ;
Camarena, C ;
De La Vega, A ;
Diaz, C ;
De Moliner, L ;
Noventa, F .
JOURNAL OF HEPATOLOGY, 1998, 29 (02) :184-190
[6]   Thinking outside the box: Recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies [J].
Briggs, AH ;
O'Brien, BJ ;
Blackhouse, G .
ANNUAL REVIEW OF PUBLIC HEALTH, 2002, 23 :377-401
[7]   Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs [J].
Brisson, M. ;
Edmunds, W. J. .
MEDICAL DECISION MAKING, 2006, 26 (05) :434-446
[8]   Hepatitis B in children [J].
Broderick, AL ;
Jonas, MM .
SEMINARS IN LIVER DISEASE, 2003, 23 (01) :59-68
[9]   Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization [J].
Chang, MH .
LIVER INTERNATIONAL, 2003, 23 (05) :309-314
[10]  
Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E